Apogee reports Q1 net loss $32.1M, cash $816M, advances pipeline with Phase 2 start for APG777 and $483M raise

Apogee Therapeutics, Inc.

2024-Q1 EPS reported -$0.64

Net loss $32.1M vs $12.5M YoY; R&D expenses $28.7M (up from $8.5M) as pipeline progresses.
Cash, equivalents and marketable securities $816.2M; runway into early 2028.
Completed upsized public offering raising $483M gross proceeds at $62.00/share.
Initiated Phase 2 trial of APG777 (IL-13) in atopic dermatitis; proof-of-concept data expected 2H 2025.
Dosed first participant in Phase 1 trial of APG808 (IL-4Rα); interim data expected 2H 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Apogee Therapeutics, Inc. reported financial results for first quarter 2024.

Period: first quarter 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Apogee Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Apogee Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-060195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.